Antibodies in development
In addition to vaccines, Intercell is developing antibodies against infection diseases including Staphylococcus aureus and other hospital-acquired bacterial infections, Pneumococcus, Group A Streptococcus and Group B Streptococcus.
About Monoclonal Antibodies
Antibodies are an important part of the body's natural defense system and are normally produced by our immune system to help our bodies fight disease. Antibodies are proteins that seek out, recognize and bind to a particular site on cells, bacteria and other organisms in a highly specific manner. This specificity makes antibodies useful in the treatment of many types of disease, and antibodies have relatively few side effects since they are a part of the body's own natural immune system.
Worldwide, pharmaceutical and biotechnology companies, as well as universities, are exploring monoclonal antibody technology to develop new therapeutic and in vivo diagnostic products. Therapeutic antibody products are currently on the market for a variety of indications, including cancer, heart disease, and transplant rejection. To date, 17 monoclonal antibody products are approved by the U.S. Food and Drug Administration for use as therapeutic products in the United States.
Partners
- S. aureus antibodies: Merck & Co., Inc.
- Pneumococcus antibodies: Kyowa Hakko Kirin
- Group A Streptococcus antibodies: In-house
- Group B Streptococcus antibodies: In-house